Jiabeini Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiabeini Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Caiyun Bai
Department of Breast Surgery, General Surgery Center The First Hospital of Jilin University Changchun Jilin China
1 shared publicationFengjiang Qu
Department of Emergency Surgery The First Hospital of Jilin University Changchun Jilin China
1 shared publication- Keman Cheng
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China
1 shared publication Pin Gao
Department of Breast Surgery, General Surgery Center The First Hospital of Jilin University Changchun Jilin China
1 shared publicationSijie Li
Department of Breast Surgery, General Surgery Center The First Hospital of Jilin University Changchun Jilin China
1 shared publicationTianyu Shao
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology of China Beijing China
1 shared publication
Latest Publications
- Open Access
- 19 February 2026
- Published by Wiley in Advanced Science
- Vol. 13 (29) , e21684
Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects
Cancer immunotherapy is increasingly moving toward personalized, precision‐based strategies, with cancer vaccines emerging as a promising approach to reshape treatment. However, despite their potential, current tumor vaccines often yield limited clinical responses and subpar immunogenicity, underscoring the urgent need for innovative delivery systems to enhance immune activation. Bacterial outer membrane vesicles (OMVs), which possess natural immunomodulatory properties and impressive engineering flexibility, have attracted attention as versatile platforms for vaccine development and bioengineering applications. This review thoroughly summarizes recent advances in using OMVs to enhance the effectiveness of cancer vaccines. First, we explain the key biological features of OMVs that support their immunotherapeutic potential. Next, we carefully analyze the primary mechanisms by which OMVs enhance immune responses, as well as cutting‐edge engineering strategies to improve their safety, immunogenicity, and specificity. Additionally, we discuss the significant challenges that hinder the clinical use of OMV‐based cancer vaccines and provide a comprehensive review of current progress and future outlooks. Looking forward, combining artificial intelligence, tumor microenvironment profiling, and neoantigen discovery is expected to drive the development of next‐generation, personalized OMV‐based immunotherapies. Overall, OMVs stand out as a transformative platform capable of overcoming major obstacles in cancer vaccine development and pushing forward future cancer immunotherapy.
- 19 February 2026
- Published by Wiley in Advanced Science
- Vol. 13 (29) , e21684
Open AccessBacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects
Cancer immunotherapy is increasingly moving toward personalized, precision‐based strategies, with cancer vaccines emerging as a promising approach to reshape treatment. However, despite their potential, current tumor vaccines often yield limited clinical responses and subpar immunogenicity, underscoring the urgent need for innovative delivery systems to enhance immune activation. Bacterial outer membrane vesicles (OMVs), which possess natural immunomodulatory properties and impressive engineering flexibility, have attracted attention as versatile platforms for vaccine development and bioengineering applications. This review thoroughly summarizes recent advances in using OMVs to enhance the effectiveness of cancer vaccines. First, we explain the key biological features of OMVs that support their immunotherapeutic potential. Next, we carefully analyze the primary mechanisms by which OMVs enhance immune responses, as well as cutting‐edge engineering strategies to improve their safety, immunogenicity, and specificity. Additionally, we discuss the significant challenges that hinder the clinical use of OMV‐based cancer vaccines and provide a comprehensive review of current progress and future outlooks. Looking forward, combining artificial intelligence, tumor microenvironment profiling, and neoantigen discovery is expected to drive the development of next‐generation, personalized OMV‐based immunotherapies. Overall, OMVs stand out as a transformative platform capable of overcoming major obstacles in cancer vaccine development and pushing forward future cancer immunotherapy.